ArticleInternational journal of molecular sciences2019
Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Pooled it
- Relationship of fibroblast growth factor 21, Klotho, and diabetic retinopathy: a meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Photobiology in ophthalmology: from evolutionary adaptation to translational therapeutics.Japanese journal of ophthalmology · 2026Review
- Fibrates : Do They Still Have a Role in Therapy in 2025?Current atherosclerosis reports · 2025Review
- FGF21 ameliorates septic liver injury by restraining proinflammatory macrophages activation through the autophagy/HIF-1α axis.Journal of advanced research · 2025Article
- Expression and Secretion of Intraocular Fatty Acid-Binding Protein 4 (ioFABP4) and 5 (ioFABP5) Are Regulated by Glucose Levels and Fatty Acids.International journal of molecular sciences · 2025Article
- Future Directions in Diabetic Retinopathy Treatment: Stem Cell Therapy, Nanotechnology, and PPARα Modulation.Journal of clinical medicine · 2025Review
- Retinal ischemic diseases and promising therapeutic molecular targets.Histology and histopathology · 2025Review
- Lessons from PROMINENT and prospects for pemafibrate.Cardiovascular diabetology · 2024Article
- The Role of HIF-1α in Retinopathy of Prematurity: A Review of Current Literature.Journal of clinical medicine · 2024Review
- Therapeutic Effects of Anti-Inflammatory and Anti-Oxidant Nutritional Supplementation in Retinal Ischemic Diseases.International journal of molecular sciences · 2024Review
- Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?Neural regeneration research · 2023Article
- Diabetic Neuropathy of the Retina and Inflammation: Perspectives.International journal of molecular sciences · 2023Review
- FGF21 Depletion Attenuates Colitis through Intestinal Epithelial IL-22-STAT3 Activation in Mice.Nutrients · 2023Article
- Therapeutic roles of PPARα activation in ocular ischemic diseases.Histology and histopathology · 2023Review
- Article
- Retinal Disease and Metabolism.Life (Basel, Switzerland) · 2022Article
- PPARα Modulation-Based Therapy in Central Nervous System Diseases.Life (Basel, Switzerland) · 2021Review
- Metabolism in Retinopathy of Prematurity.Life (Basel, Switzerland) · 2021Review
- Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Large-scale clinical trials, such as the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies, have shown that the administration of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, suppresses the progression of diabetic retinopathy. In this paper, we reveal a therapeutic effect of a selective PPARα modulator (SPPARMα), pemafibrate, against pathological angiogenesis in murine models of retinopathy. Oxygen-induced retinopathy (OIR) was induced in C57BL/6J mice by exposure to 85% oxygen from postnatal day eight (P8) for 72 h. Vehicle, pemafibrate or fenofibrate was administrated by oral gavage from P12 to P16 daily. Administration of pemafibrate, but not fenofibrate, significantly reduced pathological angiogenesis in OIR. After oral pemafibrate administration, expression levels of downstream PPARα targets such as acyl-CoA oxidase 1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.